Metrika

  • citati u SCIndeksu: [2]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 7 od 7  
Back povratak na rezultate
2009, vol. 66, br. 12, str. 966-972
Polno uslovljene razlike u hipolipemičnom i antiinflamatornom delovanju statina kod bolesnika sa dijabetesom melitusom tip 2 i koronarnom bolešću
aUniverzitet u Nišu, Medicinski fakultet, Katedra Patofiziologija
bUniverzitet u Nišu, Medicinski fakultet, Katedra Fiziologija
cKlinički centar Niš, Klinika za neurologiju
dUniverzitet u Nišu, Medicinski fakultet, Institut za prevenciju, lečenje i rehabilitaciju reumatičkih i kardioloških bolesti 'Niška Banja' - Niška Banja
eUniverzitet u Nišu, Medicinski fakultet, Katedra Farmacija

e-adresaboris_dj@medfak.ni.ac.yu
Ključne reči: hidroksimetilglutaril-CoA reduktaze, inhibitori; dijabetes melitus, insulin-nezavisni; koronarna bolest; pol
Sažetak
Uvod/Cilj. Statini ispoljavaju hipolipemične i dodatne nelipidne efekte kojima deluju na markere inflamacije, popravljaju endotelnu funkciju i stabilizuju ateromatozni plak. Cilj rada bio je ispitivanje polno uslovljene razlike u hipolipemičnom i antiinflamatornom delovanju statina kod bolesnika sa dijabetesom melitusom (DM) tip 2 i koronarnom bolešću (KB). Metode. Analizirano je 60 dislipidemičnih bolesnika sa DM tip 2 i KB, na hipolipemičnom režimu sa promenom načina života i ishrane. U odnosu na tip medikamentne hipolipemične terapije bili su podeljeni u dve grupe po 30 bolesnika: na terapiji statinima (20 mg ekvivalentne doze simvastatina u trajanju od 3 meseca) i bez statinske terapije. Kod svih bolesnika vršena je procena gojaznosti i kvaliteta glikoregulacije. Određivani su lipidni i pokazatelji inflamacije: C-reaktivni protein (CRP), fibrinogen, leukocitna formula, intracelularni adhezioni molekul (ICAM-1), vaskularni adhezioni molekul (VCAM-1). Rezultati. Bolesnice sa DM tip 2 imale su izraženiju opštu i abdominalnu gojaznost, lošiju glikoregulaciju, izraženije lipoproteinske i inflamatorne poremećaje nego muškarci. Primena statina značajno popravlja lipidne pokazatelje i kvalitet glikoregulacije kod žena, a kod muškaraca značajno redukuje vrednosti LDL-C i nonHDL-C. Statinska terapija snažnije i značajnije snižava markere inflamacije kod žena nego kod muškaraca. U grupi bez statinske terapije nema ovako značajne redukcije. Koncentracije ICAM-1 su najniže kod muškaraca na terapiji statinima, dok se vrednosti VCAM-1 molekula nisu razlikovale između polova i ispitivanih grupa. Zaključak. Žene sa DM tip 2 i KB imaju teže lipoproteinske i poremećaje glikoregulacije uz izraženiji proinflamatorni profil nego muškarci. Terapija statinima značajnije popravlja kvalitet glikoregulacije i redukuje markere inflamacije kod žena. Superiorniji antiinflamatorni efekat statina kod muškaraca vidljiv je samo u značajnijoj redukciji ICAM-1.
Reference
*** (2002) The exper panel: The third report of the national education program (NCEP), expert panle on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): Final report. Circulation, 106: 3421-43
Barrett-Connor, E., Giardina, E.V., Gitt, A.K., Gudat, U., Steinberg, H.O., Tschoepe, D. (2004) Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med, 164(9): 934-42
Bickel, C., Rupprecht, H.J., Blankenberg, S., Espinola-Christine,, Rippin, G., Hafner, G., Lotz, J., Prellwitz, W., Meyer, J., atherogene Group (2002) Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol, 82(1): 25-31
Bittner, V. (2005) Perspectives on dyslipidemia and coronary heart disease in women. Journal of the American College of Cardiology, 46(9): 1628
Crisby, M., Nordin-Fredriksson, G., Shah, P.K., Yano, J., Zhu, J., Nilsson, J. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation, 103(7): 926-33
de Backer, G., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., Manger, C.V., Orth-Gomer, K., Perk, J., Pyorala, K., Rodicio, J.L. (2003) European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J, 24(17): 1601-10
Đinđić, B., Damnjanović, G., Mitrović, V., Sokolović, D. (2004) Dijabetesna dislipidemija i ateroskleroza. Vojnosanitetski pregled, vol. 61, br. 1, str. 71-75
Eccles, K.A., Sowden, H., Porter, K.E., Parkin, S.M., Homer-Vanniasinkam, S., Graham, A.M. (2008) Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis, 200(1): 69
Enriquez, J.R., Pratap, P., Zbilut, J.P., Calvin, J.E., Volgman, A.S. (2008) Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, β-blockers, or statins. Gender Medicine, 5(1): 53
Eschen, O., Christensen, J.H., Toft, E., Schmidt, E.B. (2005) Soluble adhesion molecules and marine n-3 fatty acids in patients referred for coronary angiography. Atherosclerosis, 180(2): 327-31
Fox, K., Garcia, M.A.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., i dr. (2006) Guidelines on the management of stable angina pectoris: Executive summary: The task force on the management of stable angina pectoris of the European Society of cardiology. Eur Heart J, 27, str. 1341-1381
Fukushima, H., Kugiyama, K., Sugiyama, S., Honda, O., Koide, S., Nakamura, S., Kawano, H., Soejima, H., Miyamoto, S., Yoshimura, M., Sakamoto, T., Ogawa, H. (2001) Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol, 88(12): 1370-3
Gibson, D.M., Bron, N.J., Richens, A., Hounslow, N.J., Sedman, A.J., Whitfield, L.R. (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol, 36(3): 242-6
Grundy, S.M., Cleeman, J.I., Merz, C.B., Brewer, H., Clark, L.T., Hunninghake, D.B., Pasternak, R.C., Smith, S.C., Stone, N.J., Coordinating Committee of the National Cholesterol Education Program (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol, 44(3): 720-32
Güray, U., Erbay, R.A., Güray, Y., Yilmaz, B.M., Boyaci, A.A., Sasmaz, H., Korkmaz, S., Kütük, E. (2004) Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol, 96(2): 235-40
Jenkinsa, A., Rothena, M., Kleina, R., Mollera, K., Eldridgea, L., Zhengd, D., i dr. (2008) Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. Journal of Diabetes and its Complications, 22(3): 153
Kanai, A., Kawamura, T., Umemura, T., Nagashima, M., Nakamura, N., Nakayama, M., i dr. (2008) Association between future events of brain infarction and soluble levels of intercellular adhesion molecule-1 and C-reactive protein in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 82(2): 157
Khera, A., Mcguire, D.K., Murphy, S.A., Stanek, H.G., das Sandeep, R., Vongpatanasin, W., Wians, F.H., Grundy, S.M., de Lemos, J.A. (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol, 46(3): 464-9
Larsson, C.A., Gullberg, B., Merlo, J., Rastam, L., Lindblad, U. (2005) Female advantage in AMI mortality is reversed in patients with type 2 diabetes in the Skaraborg Project. Diabetes Care, 28(9): 2246-8
Lawlor, A.D., Fraser, A., Ebrahim, S., Smith, D.G. (2007) Independent associations of fasting insulin, glucose and glycated haemoglobin with stroke and coronary heart disease in older women. PloS Med, 4(8), 1396-404
Malik, I., Danesh, J., Whincup, P., Bhatia, V., Papacosta, O., Walker, M., Lennon, L., Thomson, A., Haskard, D. (2001) Soluble adhesion molecules and prediction of coronary heart disease: A prospective study and meta-analysis. Lancet, 358(9286): 971-6
Maron, D.J., Fazio, S., Linton, M.F. (2000) Current perspectives on statins. Circulation, 101(2): 207-13
Mehner, A., Lindblad, U., Rastam, L., Bostrom, K.B. (2008) Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men. European Journal of Clinical Pharmacology, 64(8): 815
Murphy, S.A., Cannon, C.P., Wiviott, S.D., de Lemos, J.A., Blazing, M.A., Mccabe, C.H., i dr. (2007) Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 Tria. American Journal of Cardiology, 100(7): 1047
Nakajima, K. (1999) Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group. Clin Ther, 21(12): 2047-57
Natarajan, S., Liao, Y., Cao, G., Lipsitz, S.R., Mcgee, D.L. (2003) Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med, 163(14): 1735-40
Patel, S., Celermajer, D.S., Bao, S. (2008) Atherosclerosis: Underlying inflammatory mechanisms and clinical implications. Int J Biochem Cell Biol, 40, str. 576-80
Pearson, T.A., Mensah, G.A., Alexander, R., Anderson, J.L., Cannon, R.O., Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C., Taubert, K. (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3): 499-511
Ridker, P.M., Hennekens, C.H., Buring, J.E., Rifai, N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342(12): 836-43
Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F., Braunwald, E. (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100(3): 230-5
Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H., Pfeffer, M.A., Braunwald, E. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 352(1): 20-8
Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., Zeiher, A., Chaitman, B.R., Leslie, S., Stern, T., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. JAMA, 285(13): 1711-8
Sharrett, A.R., Ballantyne, C.M., Coady, S.A., Heiss, G., Sorlie, P.D., Catellier, D., Patsch, W. (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 104 (10), str. 1108-1113
Stehouwer, C.D.A., Gall, M., Twisk, J.W.R., Knudsen, E., Emeis, J.J., Parving, H. (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes, 51(4): 1157-65
Stone, N.J., Bilek, S., Rosenbaum, S. (2005) Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options. Am J Cardiol, 96(4A): 53E-59E
Tahara, N., Kai, H., Ishibashi, M., Nakaura, H., Kaida, H., Baba, K., i dr. (2006) Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. Journal of the American College of Cardiology, 48(9): 1825
Tani, S., Nagao, K., Anazawa, T., Kawamata, H., Iida, K., Matsumoto, M. (2008) Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. Atherosclerosis, 198(2): 360
Tousoulis, D., Antoniades, C., Koumallos, N., Stefanadis, C. (2006) Pro-inflammatory cytokines in acute coronary syndromes: From bench to bedside. Cytokine & Growth Factor Reviews, 17(4): 225
van de Ree, M.A., Huisman, M.V., Princen, H.G., Meinders, A.E., Kluft, C., DALI-Study Group (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis, 166(1): 129-35
Wu, Y., Ip, J.E., Huang, J., Zhang, L., Matsushita, K., Liew, C.C., i dr. (2006) Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circulation Research, 99(3): 315
Zapolska, D., Siennicka, A., Kaczmarczyk, M., Kolodziej, B., Naruszewicz, M. (2004) Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells. Life Sci, 75(11): 1287-302
 

O članku

jezik rada: srpski
vrsta rada: originalan članak
DOI: 10.2298/VSP0912966D
objavljen u SCIndeksu: 12.01.2010.